A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis



Status:Recruiting
Conditions:Neurology, Neurology, Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - Any
Updated:3/21/2019
Start Date:September 10, 2018
End Date:July 11, 2022
Contact:US Biogen Clinical Trial Center
Email:clinicaltrials@biogen.com
Phone:866-633-4636

Use our guide to learn which trials are right for you!

A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

The primary objective of this study is to evaluate the safety and tolerability of BIIB078 in
adults with C9ORF72-ALS. The secondary objective of this study is to evaluate the
pharmacokinetic profile of BIIB078.


Key Inclusion Criteria:

- Ability of the subject to understand the purpose and risks of the study, to provide
signed and dated informed consent, and to authorize the use of confidential health
information in accordance with national and local subject privacy regulations; or, in
the event of the subject's physical incapacity to sign, to confirm that understanding
and consent orally to a legally authorized representative (LAR) for the express
purpose of having said informed consent and authorization signed on his/her behalf.

- All subjects of childbearing potential must agree to practice highly effective
contraception during the study and be willing and able to continue contraception for 5
months after their last dose of study treatment.

- Must meet the possible, laboratory-supported probable, probable, or definite criteria
for diagnosing ALS according to the World Federation of Neurology El Escorial criteria
and have documentation of a clinical genetic test demonstrating the presence of a
pathogenic mutation in C9ORF72.

- Slow vital capacity (SVC) ≥ 50% of predicted value as adjusted for sex, age, and
height (from the sitting position).

- Subjects taking concomitant riluzole at study entry must be on a stable dose for ≥ 30
days prior to the first dose of study treatment (Day 1).

- Subjects taking concomitant edaravone at study entry must be on a stable dose for ≥ 60
days prior to the first dose of study treatment (Day 1).

- ALS Cognitive Behavioral Screen (ALS-CBS) score ≥ 11 for the cognitive portion; ≥ 33
for the behavioral portion.

- Medically able to undergo the study procedures, and to adhere to the visit schedule at
the time of study entry, as determined by the Investigator.

- Screening values of coagulation parameters including platelet count, international
normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin
time (APTT) should be within normal ranges.

- Has an informant/caregiver who, in the Investigator's judgment, has frequent and
sufficient contact with the subject as to be able to provide accurate information
about the subject's cognitive and functional abilities at Screening.

Key Exclusion Criteria:

- History of drug abuse or alcoholism ≤ 6 months of Screening that would limit
participation in the study, as determined by the Investigator.

- Tracheostomy.

- History of or positive test result at Screening for human immunodeficiency virus. .

- History of, or positive test result at Screening for, hepatitis C virus antibody.

- Treatment with another investigational drug or biological agent within 1 month of
Screening or 5 half-lives of study agent, whichever is longer.

- Treatment with anti-platelet or anticoagulant therapy ≤ 14 days before Screening (with
the exception of aspirin ≤ 325 mg/day) or anticipated use during the study.

- Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing
system during the study period.

- Female subjects who are pregnant or currently breastfeeding.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
We found this trial at
11
sites
?
mi
from
Montreal,
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Cambridge, MA
Click here to add this to my saved trials
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials